Partilhar
Informação da revista
Artigos originais
Does anemia affect the predictive ability of bleeding risk scores in patients with acute coronary syndromes?
Alberto Garay, Albert Ariza-Solé, Francesc Formiga, Victoria Lorente, José C. Sánchez-Salado, Joel Salazar-Mendiguchía, Gerard Roura, Guillem Muntané, ... Angel Cequier
Rev Port Cardiol. 2016;35:637-44
Open access
Mortality benefit of long-term angiotensin-converting enzyme inhibitors or angiotensin receptor blockers after successful percutaneous coronary intervention in non-ST elevation acute myocardial infarction
María Cristina González-Cambeiro, Andrea López-López, Emad Abu-Assi, Sergio Raposeiras-Roubín, Carlos Peña-Gil, José García-Acuña, Ramón González-Juanatey
Rev Port Cardiol. 2016;35:645-53
Open access
Artigos Originais
Comentário editorial
Tratamento do enfarte do miocárdio sem elevação de ST: um eterno desafio…
Henrique Cyrne Carvalho
Rev Port Cardiol. 2016;35:655-7
Open access
Reabilitação cardíaca em Portugal. Inquérito 2013‐2014
Conceição Silveira, Ana Abreu
Rev Port Cardiol. 2016;35:659-68
Open access
Artigos Originais
Comentário editorial
Reabilitação cardíaca em Portugal. Ponto da situação em 2013‐2014
Miguel Mendes
Rev Port Cardiol. 2016;35:669-71
Open access
Bailout intravenous esmolol for heart rate control in cardiac computed tomography angiography
Sílvia Aguiar Rosa, Ruben Ramos, Hugo Marques, Rosana Santos, Cecília Leal, Helena Casado, Márcia Saraiva, Luísa Figueiredo, Rui Cruz Ferreira
Rev Port Cardiol. 2016;35:673-8
Open access
Artigos Originais
Comentário editorial
Redução da frequência cardíaca para a tomografia computorizada cardíaca: um mal necessário?
Pedro de Araújo Gonçalves
Rev Port Cardiol. 2016;35:679-80
Open access
Artigo de revisão
Choque cardiogénico – fármacos inotrópicos e vasopressores
José Amado, Paula Gago, Walter Santos, Jorge Mimoso, Ilídio de Jesus
Rev Port Cardiol. 2016;35:681-95
Open access
Casos clínicos
Anomalous pulmonary venous connection: An underestimated entity
Sara P. Magalhães, Nuno Moreno, Marília Loureiro, Manuela França, Fernanda Reis, Sílvia Alvares, Manuel Ribeiro
Rev Port Cardiol. 2016;35:697.e1-6
Open access
Causa rara de síndrome coronária aguda: síndrome de Kounis
João Almeida, Sara Ferreira, Joana Malheiro, Paulo Fonseca, Daniel Caeiro, Adelaide Dias, José Ribeiro, Vasco Gama
Rev Port Cardiol. 2016;35:699.e1-4
Open access
Percutaneous closure of isolated ostium secundum-type atrial septal defect in a patient with Mayer-Rokitansky-Küster-Hauser syndrome
Murat Akcay, Okan Gulel, Korhan Soylu, Murat Meric, Muzaffer Elmali
Rev Port Cardiol. 2016;35:701.e1-3
Open access
Imagens em cardiologia
Segmental pulmonary stenosis: Importance of computed tomography angiography
Santiago Colunga Blanco, Isaac Martínez Bendayán, Maria José Martínez Sapiña Llanas, Beatriz Bouzas Zubeldia, Fernando Rueda Nuñez, José Manuel Vázquez Rodríguez
Rev Port Cardiol. 2016;35:703-5
Open access
Unexpected diagnosis in a liver donor candidate
Betul Cengiz, Sukru Taylan Sahin, Selen Yurdakul, Ismail Polat Canbolat, Saide Aytekin
Rev Port Cardiol. 2016;35:707-8
Open access
Amorphous tumor of the mitral valve
Henrique Guedes, Nuno Moreno, Rui Cunha Sousa, Mário Jorge Amorim, Aurora Andrade, Paula Pinto
Rev Port Cardiol. 2016;35:709-10
Open access
Cartas ao editor
Novos «critérios refinados» eletrocardiográficos na avaliação de atletas
Ricardo C. Rodrigues, Gomes Serrão, Susana Gomes, Décio Pereira
Rev Port Cardiol. 2016;35:711-3
Open access
Como interpretar o eletrocardiograma do atleta?
Hélder Dores, Nuno Cardim
Rev Port Cardiol. 2016;35:715-6
Open access
Artigo recomendado do mês
Comentário a: «The SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood‐Pressure Control»
António Vaz Carneiro
Rev Port Cardiol. 2016;35:717-8
Open access
Conteúdo especial sobre COVID-19
- Clinical outcomes of percutaneous coronary intervention in chronic total occlusion in patients with type 2 diabetes mellitus
- Percutaneous coronary intervention in chronic total occlusions: Should it be avoided in type 2 diabetic patients?
- RAAS inhibitors in COVID-19: Not all are created equal. Telmisartan is the one
- Reply to: RAAS inhibitors in COVID-19: Not all are created equal. Telmisartan is the one
Publicar em
Revista Portuguesa de Cardiologia
A revista pertence ao Committee on Publication Ethics (COPE) www.publicationethics.org e adere aos seus princípios e procedimentos.